Affiliation:
1. From the Departments of Clinical Pharmacology (J.B.K., Y.H.W., J.F.M.)and Biostatistics (J.R.N.), Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
Abstract
OBJECTIVE— This study was designed to compare the pharmacodynamic effects of single doses of nateglinide (A-4166), repaglinide,and placebo on mealtime insulin secretion and glycemic control in healthy subjects.
RESEARCH DESIGN AND METHODS— Fifteen healthy volunteers participated in this open-label five-period crossover study. They received single 10-min preprandial doses of 120 mg nateglinide, 0.5 or 2 mg repaglinide, or placebo or 1 min preprandially of 2 mg repaglinide. Subjects received each dose only once, 48 h apart. Pharmacodynamic and pharmacokinetic assessments were performed from 0 to 12 h postdose.
RESULTS— Nateglinide induced insulin secretion more rapidly than 2 and 0.5 mg repaglinide and placebo (10 min preprandial), with mean rates of insulin rise of 2.3, 1.3, 1.15, and 0.8 μU ·ml-1 · min-1, respectively, over the 0- to 30-min postmeal interval. After peaking, insulin concentrations decreased rapidly in the nateglinide-treated group and were similar to placebo within 2 h postdose. After 2 mg repaglinide, peak insulin concentrations were delayed and returned to baseline more slowly than with nateglinide treatment. Nateglinide treatment produced lower average plasma glucose concentrations in the 0- to 2-h postdose interval than either dose of repaglinide and placebo (P < 0.05 vs. 0.5 mg repaglinide and placebo). Plasma glucose concentrations returned more rapidly to predose levels with nateglinide treatment than with either dose of repaglinide. Treatment with repaglinide produced a sustained hypoglycemic effect up to 6 h postdose.
CONCLUSIONS— In this single-dose study in nondiabetic volunteers, nateglinide provided a more rapid and shorter-lived stimulation of insulin secretion than repaglinide, resulting in lower meal-related glucose excursions. If similar results are observed in diabetes, nateglinide may produce a more physiological insulin secretory response with the potential for a reduced risk of postabsorptive hypoglycemia.
Publisher
American Diabetes Association
Subject
Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference20 articles.
1. Dunning BE: New non-sulfonylurea insulin secretagogues. Exp Opin Invest Drugs 6:1041-1048, 1997
2. Sato Y, Nishikawa M, Shinkai H, Sukegawa E: Possibility of ideal blood glucose control by a new oral hypoglycemic agent N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals. Diabetes Res Clin Pract 12:53-59, 1991
3. Ikenoue T, Akiyoushi M, Fujitani S, Okazaki K, Kondo N, Maki T:Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent(-)-N-(trans-4-isopropylcyclohexane-carbonyl)-D-phenylalanine(A-4166). Br J Pharmacol 120:137-145, 1997
4. Karara AH, Dunning BE, McLeod JF: The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects. J Clin Pharmacol 39: 172-179,1999
5. deSouza CJ, Russo P, Lozito R, Dunning B: Comparative effects of A-4166, sulfonylureas and repaglinide on meal induced glucose excursions in normal rats (Abstract). Diabetologia 40: A45,1997
Cited by
63 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献